Detalles de la búsqueda
1.
Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry.
Ann Rheum Dis
; 2024 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38594056
2.
Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis.
Eur J Clin Invest
; 54(2): e14095, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37715584
3.
Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry.
Arthritis Res Ther
; 26(1): 57, 2024 02 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38395899
4.
Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years.
Sci Rep
; 11(1): 15051, 2021 07 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34302036
5.
Retention of golimumab treatment following discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases: An analysis of the Spanish BIOBADASER registry.
Musculoskeletal Care
; 20(2): 403-407, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34668303
Resultados
1 -
5
de 5
1
Próxima >
>>